Literature DB >> 7922305

Tumor spectrum analysis in p53-mutant mice.

T Jacks1, L Remington, B O Williams, E M Schmitt, S Halachmi, R T Bronson, R A Weinberg.   

Abstract

BACKGROUND: The p53 tumor suppressor gene is mutated in a large percentage of human malignancies, including tumors of the colon, breast, lung and brain. Individuals who inherit one mutant allele of p53 are susceptible to a wide range of tumor types. The gene encodes a transcriptional regulator that may function in the cellular response to DNA damage. The construction of mouse strains carrying germline mutations of p53 facilitates analysis of the function of p53 in normal cells and tumorigenesis.
RESULTS: In order to study the effects of p53 mutation in vivo, we have constructed a mouse strain carrying a germline disruption of the gene. This mutation removes approximately 40% of the coding capacity of p53 and completely eliminates synthesis of p53 protein. As observed previously for a different germline mutation of p53, animals homozygous for this p53 deletion mutation are viable but highly predisposed to malignancy. Heterozygous animals also have an increased cancer risk, although the distribution of tumor types in these animals differs from that in homozygous mutants. In most cases, tumorigenesis in heterozygous animals is accompanied by loss of the wild-type p53 allele.
CONCLUSION: We reaffirm that p53 function is not required for normal mouse development and conclude that p53 status can strongly influence tumor latency and tissue distribution.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7922305     DOI: 10.1016/s0960-9822(00)00002-6

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  847 in total

1.  Different responses of epidermal and hair follicular cells to radiation correlate with distinct patterns of p53 and p21 induction.

Authors:  S Song; P F Lambert
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

2.  Mutations in the WRN gene in mice accelerate mortality in a p53-null background.

Authors:  D B Lombard; C Beard; B Johnson; R A Marciniak; J Dausman; R Bronson; J E Buhlmann; R Lipman; R Curry; A Sharpe; R Jaenisch; L Guarente
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

3.  The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest.

Authors:  S Wang; M Guo; H Ouyang; X Li; C Cordon-Cardo; A Kurimasa; D J Chen; Z Fuks; C C Ling; G C Li
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

4.  The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest.

Authors:  J R Yeh; R Mohan; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis.

Authors:  Lydie Pani; Melissa Horal; Mary R Loeken
Journal:  Genes Dev       Date:  2002-03-15       Impact factor: 11.361

6.  Regulation of Cdc42-mediated morphological effects: a novel function for p53.

Authors:  Gilles Gadéa; Laure Lapasset; Cécile Gauthier-Rouvière; Pierre Roux
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

7.  Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance.

Authors:  Eric J Brown; David Baltimore
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

Review 8.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

9.  DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.

Authors:  W M Tong; M P Hande; P M Lansdorp; Z Q Wang
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

10.  A mouse model of human oral-esophageal cancer.

Authors:  Oliver G Opitz; Hideki Harada; Yasir Suliman; Ben Rhoades; Norman E Sharpless; Ralph Kent; Levy Kopelovich; Hiroshi Nakagawa; Anil K Rustgi
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.